News | Amgen
WEBAMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) 06.03.2024. AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE.
Amgen Inc. (AMGN) Latest Stock News & Headlines - Yahoo Finance
WEBGet the latest Amgen Inc. (AMGN) stock news and headlines to help you in your trading and investing decisions.
Press Releases - Amgen Inc.
WEBAug 29, 2024 · news release 06.05.2024. amgen announces positive results for phase 3 registrational trial evaluating uplizna® (inebilizumab-cdon) for treatment of immunoglobulin g4-related disease (igg4-rd)
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
WEBAug 4, 2022 · Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease. Tavneos Adds to Amgen 's Decades-Long Leadership in Inflammation and Nephrology.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY ... - Amgen
WEBMay 16, 2024 · FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER. Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor. IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median ...
Amgen quarterly profit rises 15%, obesity drug trials are on track
WEBFeb 6 (Reuters) - Amgen (AMGN.O) on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of...
Amgen Seeks Expanded US Approval For Autoimmune Disease …
WEBJun 5, 2024 · On Wednesday, Amgen Inc (NASDAQ: AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna (inebilizumab-cdon) for Immunoglobulin G4-related disease, a...
Amgen (AMGN) Rises Higher Than Market: Key Facts - Yahoo …
WEB3 days ago · Amgen (AMGN) ended the recent trading session at $335.26, demonstrating a +0.85% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.13%.
NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL …
WEBTHOUSAND OAKS, Calif., May 26, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago and virtually.
Amgen dives deeper into rare disease drugs with $27.8 bln …
WEBDec 12, 2022 · Amgen shares dipped less than 1% to close at $276.78. With the deal, Amgen gains two fast-growing drugs, the thyroid eye disease treatment Tepezza and gout treatment Krystexxa.
- Some results have been removed